Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24938386 | 0.88 | ALDH1A1 (0.48) | ALDH1A1MAOBMAOAMAPK1TSHR | |
| SCHEMBL16933963 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAOBMAOAMAPK1TSHR | |
| SCHEMBL3563744 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAOBMAOAMAPK1TSHR | |
| SCHEMBL2802312 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MAOBMAOAMAPK1TSHR | |
| SCHEMBL28888551 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MAOBMAOAMAPK1TSHR | |
| SCHEMBL686929 | 0.80 | — | — | |
| SCHEMBL29661770 | 0.80 | — | — | |
| SCHEMBL31264394 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAOBMAOAMAPK1TSHR | |
| SCHEMBL31435779 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAOBMAOAMAPK1TSHR | |
| SCHEMBL9796676 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAOBMAOAMAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230192767-A1 | IL-2RGAMMA BINDING COMPOUNDS | MCMEEKIN, DERMOT (GB) | 2023-06-22 | — | — | US | disclosed |
| CN-115925790-A | Methods for synthesizing alpha 4 beta 7 peptide antagonists | 领导医疗有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230063321-A1 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | PROTAGONIST THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11548914-B2 | IL-2Rgamma binding compounds | MEDIKINE, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| CN-115038457-A | Methods for treating inflammatory bowel disease using alpha 4 beta 7 integrin antagonists | 普罗塔格尼斯特治疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220275026-A1 | IL-2RBETA BINDING COMPOUNDS | SAMSARA BIOCAPITAL, L.P. | 2022-09-01 | — | — | US | disclosed |
| EP-4023667-A1 | IL-2 RECEPTOR BINDING COMPOUNDS | Medikine, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11358986-B2 | IL-2RBETA binding compounds | MEDIKINE, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2016054411-A1 | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054445-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | PROTAGONIST THERAPEUTICS, INC. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2015176035-A1 | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-6043398-A | WATER-SOLUBLE, SULFONATED DIPHOSPHINES COMPLEXED WITH A TRANSITION METAL TO FORM HYDROFORMYLATION CATALYSTS; OUTSTANDING SURFACE ACTIVE PROPERTIES IN TWO PHASE CATALYSIS OF TWO PHASE HYDROFORMYLATION OF OCT-1-ENE OLEFINS | CELANESE INTERNATIONAL CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| US-5929273-A | METALLATION OF ARYLPHOSPHINE HALIDE BY HEATING AND PRESSURIZING IN SUITABLE CONDITIONS TO FORM ARYLPHSPHINIDE, COUPLING THE FORMED INTERMEDIATE WITH ORGANIC HALIDE TO FORM ARYL DIPHOSPHINE | CELANESE INTERNATIONAL CORP (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0898573-A1 | ARYL DIPHOSPHINES AND CATALYSTS CONTAINING THE SAME | Hoechst Celanese Corporation (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5817775-A | HYDROFORMYLATION CATALYST | CELANESE INTERNATIONAL CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| US-5777087-A | Aryl diphosphines and catalysts containing the same | CELANESE INTERNATIONAL CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997039005-A1 | ARYL DIPHOSPHINES AND CATALYSTS CONTAINING THE SAME | HOECHST CELANESE CORPORATION (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | ITGB7, EPCAM, ITGB4 | ALDH1A1 2354/4885MAOB 4686/4885MAOA 4882/4885 |
| US-20230063321-A1 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | ITGB7, ITGB4, ITGA4 | ALDH1A1 2526/4885MAOB 4689/4885MAOA 4866/4885 |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | EPCAM, SELPLG, VCAM1 | ALDH1A1 2562/4885MAOB 4861/4885MAOA 4878/4885 |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ANXA7, GRB7 | ALDH1A1 3588/4885MAOB 4618/4885MAOA 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.